Moderna (MRNA) was the worst-performing stock in the 澳洲幸运5官方开奖结果体彩网:S&P 500 on Monday as shares lost over 6% after the biotech firm said it “remains comfortable” with its full-year guidance, but warned that it couldn’t predict exact demand for its COVID-19 vaccines yet. The comments came after rival Pfizer (PFE) slashed its full-year outlook “Solely due to COVID products.”

Moderna noted in a regulatory filing it expects 2023 sales of between $6 billion and $8 billion, reiterating what it reported in its second quarter earnings release in August. The company had previously estimated that if the U.S. market for vaccines is approximately 50 million doses, it expected to be in the bottom half of that revenue range, and if the number jumps to 100 million doses, it should be in the top half.

Moderna explained that it's “still too early in the U.S. vaccination season to accurately project where vaccination rates will land for the full year.”

The company anticipates it “will have improved visibility about the expected U.S. market size” at the end of the month, and will provide 🤪an update during its earnings call Nov. 2.

Moderna shares fell to their lowest level in almost three years following the news. Pfizer shares, however, advanced after Jefferies upgraded the stock, identifying it as an opportunity.